硼替佐米联合环磷酰胺治疗多发性骨髓瘤的应用与优越性分析  

Application of bortezomib combined with cyclophosphamide in the treatment of multiple myeloma and its superiority analysis

作　　者：戚永磊[1] 赵莹[1] 陈焯文[1] QI Yong-lei;ZHAO Ying;CHEN Zhuo-wen(Department of Blood Lymphology, Foshan City First People’s Hospital, Foshan 528000, China)

机构地区：[1]佛山市第一人民医院血液淋巴科,528000

出　　处：《中国现代药物应用》2017年第14期4-6,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探究硼替佐米联合环磷酰胺治疗多发性骨髓瘤的优越性。方法 80例多发性骨髓瘤患者为研究对象,随机分为观察组与对照组,每组40例。以低剂量硼替佐米联合地塞米松为基础治疗方案,对照组联合沙利度胺治疗,观察组联合环磷酰胺治疗,治疗9周后比较两组患者近期治疗效果和治疗期间不良反应情况。结果观察组患者的完全缓解(CR)率为30.00%,深度反应率为80.00%,均显著高于对照组的10.00%、45.00%,差异有统计学意义(P<0.05)。两组患者不良反应发生情况比较差异无统计学意义(P>0.05)。结论对于多发性骨髓瘤患者使用硼替佐米联合环磷酰胺加以治疗,安全性强,近期效果显著,值得进一步推广。Objective To explore the superiority of bortezomib combined with cyclophosphamide inthe treatment of multiple myeloma.Methods A total of80multiple myeloma patients as study subjects wererandomly divided into observation group and control group,with40cases in each group.The therapeutic regimenwas based on low-dose bortezomib and dexamethasone,and the control group was treated with thalidomide.The observation group was treated with cyclophosphamide.After9weeks of treatment,short-term therapeuticeffect and adverse reactions during treatment were compared in two groups.Results The observation grouphad complete remission(CR)rate as30.00%and depth reaction rate as80.00%,which were all significantlyhigher than10.00%and45.00%in the control group,and their difference had statistical significance(P<0.05).Both groups had no statistically significant difference in occurrence of adverse reaction(P>0.05).ConclusionCombination of bortezomib and cyclophosphamide in the treatment of multiple myeloma patients is safe and it hasremarkable short-term effect.So it is worthy of further promotion.

关 键 词：硼替佐米 环磷酰胺 多发性骨髓瘤 优越性 

分 类 号：R733.3[医药卫生—肿瘤]